App-Quantinova.ai

Association of the number of dissected lymph node (LN) with the survivals of locally advanced esophageal squamous cell carcinoma (ESCC) patients received preoperative chemoradiotherapy (CRT) followed by surgery.

Jhe-Cyuan Guo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

FDG-PET/CT in the prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction.

Tomas Harustiak - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Cisplatin

The real life outcomes of modified docetaxel and cisplatin plus fluorourasil regimen in patients with metastatic gastric cancer.

Tulay Eren - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Cisplatin

Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC).

Laura Toppo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).

Annette Van Zweeden - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Translating a clinical trial to daily practice: Outcome of palliative treatment in patients with advanced cholangiocarcinoma and gallbladder cancer in the Netherlands.

Joeri Dierks - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.

Jennifer Rachel Eads - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.

Nebi Serkan Demirci - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hereditary pancreatitis

Cisplatin

Split dose gemcitabine/ cisplatin (GC) in urothelial carcinoma of the bladder: Review of toxicity and response.

Laura Elizabeth Sellers - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cisplatin

ToTem: A phase Ib trial of temisirolimus with gemcitabine and cisplatin.

Simon Pacey - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

Outcomes of patients treated with paclitaxel, ifosfamide and cisplatin (TIP) for relapsed germ cell tumour (GCT).

Mariam Jafri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

Treatment of advanced seminoma with 3 cycles of etoposide-cisplatin chemotherapy (EP120): A single-centre retrospective cohort study.

Ankit Rohit Rao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Seminoma

Cisplatin

Chemotherapy efficacy and prognosis of patients with mediastinal seminoma. Single institution experience.

Mikhail Fedyanin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Seminoma

Cisplatin

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.

Peter S. Grimison - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

Cisplatin

The impact of pathologic characteristics (lymphovascular invasion/squamous differentiation) on the efficacy of adjuvant chemotherapy for patients with upper tract urothelial cancer.

Yi-Huei Chang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cisplatin

Phase III randomized trial of comparing chemoradiotherapy vs. radiotherapy alone in lymph node negative patients with early-stage cervical cancer following radical hysterectomy.

Congying Xie - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

Cisplatin

Applicability of the concept of platinum sensitivity to recurrent cervical cancer: A JGOG Net Work study.

Munetaka Takekuma - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

Cisplatin

Early clinical results of a phase II trial evaluating neoadjuvant chemotherapy followed by chemoradiation and maintenance gefitinib in locally advanced cervical cancer.

Rony Benson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

Cisplatin

Which is better? Carboplatin versus cisplatin for locally advanced cervical cancer chemo-radiation: Peruvian experience.

Natalia Valdiviezo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

Cisplatin

Neoadjuvant chemotherapy in cervical cancer patients: a single institution experience.

Matilde Destefanis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

Cisplatin

Filters

3952 Abstracts